Results 191 to 200 of about 134,430 (328)
Immunotherapy for locally advanced and metastatic basal cell carcinoma: a narrative review. [PDF]
Li X, Wang H, Lu Q.
europepmc +1 more source
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li +17 more
wiley +1 more source
Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec. [PDF]
Che Y +3 more
europepmc +1 more source
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome [PDF]
Glen J. Weiss +7 more
openalex +1 more source
Oxidative phosphorylation (OXPHOS) activity serves as a critical metabolic determinant of radiotherapy outcomes in esophageal squamous cell carcinoma (ESCC). The CEBPB/AREG/EREG axis drives radioresistance in ESCC by reprogramming OXPHOS. AREG and EREG function as predictive biomarkers for nCRT response and prognosis of ESCC patients.
Zhang Lin +15 more
wiley +1 more source
Metastatic basal cell carcinoma of the face- Presentation of a rare case
Dimitra Maniati +5 more
openalex +1 more source
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin +6 more
wiley +1 more source
Successful Radiotherapy for Metastatic Basal Cell Carcinoma to the Parotid Gland in a Patient With Gorlin-Goltz Syndrome. [PDF]
Neaga S +4 more
europepmc +1 more source

